Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on Ashtead Group

(Sharecast News) - Analysts at Berenberg lowered their target price on industrial equipment rental company Ashtead Group from 7,000.0p to 6,000.0p on Monday but said the stock still held "high-quality rebound potential". Berenberg said Ashtead's share price has "hit the trough", in its view, and thinks there are catalysts that could lead to upside risk to FY26 guidance. Berenberg, which reiterated its 'buy' rating on Ashtead, also said growth and margin drivers remained strong in the mid-term.

"We cut our price target for Ashtead from £70 to £60 on the back of our lower growth forecasts for FY 26, primarily due to construction environment uncertainty, but remain bullish about the group's upside potential," said Berenberg.

The German bank noted that Ashtead underperformed its peers in 2024, but said much of this was due to high end-market exposure to local markets, while the other limiting factor appeared to be soft acquisition spend.

"We think this could be a sign of another share buyback, which could limit the impact of index outflows from Ashtead's planned Q126 US listing," noted Berenberg.

The analysts also highlighted that the stock trades on a seven times enterprise value to underlying earnings ratio for the next twelve months - a 10% discount to its five-year history and a one-turn discount to rival United Rentals.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.